BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz

BridgeBio Pharma Inc. (NASDAQ:BBIO) is drawing renewed investor attention as the biotech company advances a slate of rare-disease therapies toward potential regulatory filings and commercial launches.

William Blair initiated coverage on the commercial-stage biotech, highlighting the company’s expanding pipeline of treatments targeting rare genetic conditions.

BridgeBio’s Unique Position

Analyst John Boyle wrote, “BridgeBio is in a unique position with an accelerating launch in Attruby, near-term NDA submissions for disease-modifying therapies setting up late-2026/early-2027 launches, and regulatory submission…”

The analyst initiated coverage with an Outperform rating and a fair value of $93.03 per share.

BridgeBio Pharma’s Attruby (acoramidis) is well-positioned for growth in ATTR-CM. The second-generation stabilizer is competing with Alnylam Pharmaceutical Inc.’s (NASDAQ:ALNY) Amvuttra (vutrisiran, a silencer) and Pfizer Inc.’s (NYSE:PFE) Vyndamax (tafamidis, a first-generation stabilizer).

While investors often debate the clinical profiles among the three products, analyst Boyle writes that market surveys have indicated that, for the frontline setting, prescribers view both Attruby and Amvuttra as next-generation products superior to tafamidis.

Pfizer’s Tafamidis remains the market leader, with roughly $6 billion in sales annualized, but the usage of second-generation products such as Attruby and Amvuttra is growing rapidly.

Potential Generic Entry Risk For BridgeBio

William Blair sees some risk from potential generic entry in late 2028, but believes the threat is lower than widely perceived.

Attruby’s stronger TTR stabilization and simple twice-daily dosing support a solid efficacy and adherence case, which could justify premium pricing even if generics enter the market.

The analyst models 2035 U.S. Attruby sales of $3.4 billion.

Market Opportunities For BridgeBio’s Other Rare Disease Drugs

Pivotal PROPEL 3 study data of infigratinib in achondroplasia (ACH) show a best-in-class efficacy profile with a favorable once-daily oral formulation.

In February, the company shared positive topline results from PROPEL 3 Phase 3 pivotal study of oral infigratinib in children with achondroplasia.

While BioMarin Pharmaceutical Plc’s (NASDAQ:BMRN) Voxzogo has improved management of ACH, its daily injection requirement remains a notable burden.

A once-daily oral therapy like infigratinib could offer meaningful differentiation.

William Blair also sees significant rare-disease market opportunities in encaleret in ADH1.

In October 2025, BridgeBio Pharma’s CALIBRATE Phase 3 study of encaleret in autosomal dominant hypocalcemia type 1 (ADH1) met its primary endpoint.

BBIO Price Action: BridgeBio Pharma shares were up 12.60% at $73.91 at the time of publication on Tuesday, according to Benzinga Pro data.

Image via Shutterstock

This article BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz originally appeared on Benzinga.com